Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological AutoImmune Disease Bullous Pemphigoid

NEW YORK Feb. 28 2017 PRNewswire Immune Pharmaceuticals Inc. Nasdaq IMNP "Immune" or the "Company" today announced that it has broadened enrollment eligibility criteria based on the data reported from three patients that have completed...